despit concern bring ci closer
ci beat rais pressur concern around pbm
ramp higher scrutini warrant guid maintain
enter august mco usual good handl cost trend meanwhil pbm
earn actual came better ests/consensus/mgmt expect
make ramp easili achiev combin signific beat
conserv yet meaning rais lend support ci commentari
thing perform well market give credit final ci guid
pbm earn growth make first time street yardstick
judg compani against- set stage overhang remov
rais est increas visibl earn po unchang
base ep vs previous roll forward valuat
methodolog upsid number start reflect
estim maintain buy lost market reaction ci beat pbm consensu est beat
significantli rais conserv still share repo upsid
appear issu street vs perform
ci report expect y/i growth drive return
health insur free addit esrx higher part biz higher individu
return normal margin out-performance note issu
known come therefor varianc vs compani
expect meanwhil ci character in-lin across three product
back maintain annual trend guidanc rais health plan
profit expect make street skeptic difficult understand
fischbeck focu pars esrx growth
quarter focu express script esrx y/i growth outlook
vs estim profit declin around similar analyz
reason jump posit margin although jump may
signific actual would larg follow last year earn season overal
pivot growth give us comfort lt earn potenti segment set
clear event investor stop overli discount pbm earn
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
total benefit claim
total invest
oper return averag asset
long term debt cap ratio ex fa
amtz dac pre-tax profit bef amtz dac
one largest manag
organ pharmaci benefit manag
us compani also offer global
supplement benefit disabl life
esrx deal add capabl cash-flow
potenti ep upsid think ci could
achiev close low end pro forma
ep target year earli
compel aspect deal
gener much pf parent
combin
fischbeck focu section choos theme explor detail either
respons recent investor question unexpect develop
quarter quarter focu express script esrx y/i growth
outlook vs estim profit declin around similar
analyz reason jump posit margin although
jump may signific actual would larg follow last year earn season
overal pivot growth give us comfort lt earn potenti
segment set clear event investor stop overli discount
esrx guid impli ci grow pbm y/i
given esrx weak perform head deal potenti legisl chang
ci investor cautiou around pbm segment want see earn
growth vs legaci esrx determin actual growth complex usual given
ci reseg busi line part deal move esrx part
busi health plan busi move ci legaci mail order busi
pbm segment result number adjust make
first half year appear segment perform expect
estim earn would appear
put ci guidanc incom growth risk
headwind becom tailwind
calcul compar earn y/i first bridg histor esrx ebitda
compar pre-tax earn number subtract legaci cost
cut initi adjust non-cor factor distort ci
earn resegment strand overhead synergi end analysi
impli core earn order
midpoint guidanc ci would need grow pivot
neg growth posit growth left investor skeptic fact
compani commit singl digit earn growth give market
firm measur stick hit set earn report
clear event investor stop discount pbm earn
ci note number headwind occur caus year year
declin suppli chain initi usual happen around year end delay
merger leav initi higher cost structur resolv
set momentum time gener launch
usual initi pbm profit hurt y/i growth rate given
launch fewer launch continu perform
specialti drug dynam play estim ci pbm earn actual
project grow y/i next two quarter appl appl core
basi compani hit midpoint guidanc
tabl esrx scorecard ci track pivot pbm growth
bridg compar report earn histor esrx result
tabl esrx scorecard ci track pivot pbm growth
bridg compar report earn histor esrx result
ci bridg core earn
number given/impli manag black number adjust analyst day green number calcul analysi
season within variat legaci esrx
although chang y/i growth rate vs look high ramp ci
project actual match quit well esrx histor season note ci
earn pbm earn compar esrx
look quarter vs percentag annual earn within
prior slightli slightli dynam make
sens us addit initi mention larg deal
would expect result ramp integr synergi ramp
chart cigna earn ramp isnt differ esrx less variat
conclus esrx pivot growth clear event
ci abl show earn growth esrx remov signific overhang
help lift see overli discount valuat result see earn
bigger potenti catalyst offici guidanc pbm earn growth
measur stick judg perform end day
meaning beat rais probabl best indic stori remain track
give signific weight compani commentari rebound
fact result increas comfort level high end guidanc
color guidanc
consist past practic compani exclud futur capit deploy
pyd guidanc addit ci guidanc also exclud transit
client pharmaci benefit manag pbm busi
adjust revenu guid rais increas outlook script
growth roughli relat earli ci transit script optumrx
contract partial off-set reduct expect medic custom growth ci
miss consensu medic loss ratio expect quarter indic
result in-lin compani expect reiter trend
guidanc give us comfort issu
function street mis-model season addit compani lower
expect sg tax rate midpoint respect
compani reiter ep goal lt ep growth
see increment indic ci track deliv
confid ci high end rang
adjust incom oper
adjust pre-tax incom op
deploy
po base ep estim stock five-year averag pe
ratio feel conserv multipl
risk po deal integr risk issu disabl life busi
compani see higher expect cost trend potenti impact futur
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
